Conditions

Subcategories:Axial Spondyloarthritis Clinical Criteria/Guidelines Gout and Crystalline Arthritis Myositis Osteoarthritis and Bone Disorders Other Rheumatic Conditions Pain Syndromes Pediatric Conditions Psoriatic Arthritis Rheumatoid Arthritis Sjögren’s Disease Soft Tissue Pain Systemic Lupus Erythematosus Systemic Sclerosis Vasculitis

Tofacitinib Shows Early Potential for Treating Dermatomyositis

Carina Stanton | January 16, 2019

A proof-of-concept study including 10 patients treated for dermatomyositis with tofacitinib, an FDA-approved drug for RA and psoriatic arthritis, shows strong clinical efficacy…

Intensive Patient Education May Not Be Helpful for Acute Low Back Pain

Lara C. Pullen, PhD | January 14, 2019

Education with recommended first-line care may not improve pain outcomes in patients with acute low back pain. When comparing patients who received education with those who received professional consultation without information or advice, researchers found patient education was no more effective than placebo at reducing depression or incidence of chronic low back pain…

Intronic Polymorphism Associated with Risk of Neurological Disorders in SLE

Lara C. Pullen, PhD | January 8, 2019

Patients who develop neuropsychiatric symptoms of SLE have a small nucleotide polymorphism (SNP) in an intron in a Ca++ ion channel gene that influences some, but not all, events regulated by Ca++. The SNP appears to influence activation induced apoptosis rates and cytokine production, specifically IL-4, in a disease- and genotype-specific manner…

SLE Patients May Not Receive Enough Cardiovascular Disease Assessment & Treatment

Arthritis Care & Research | January 2, 2019

Systemic lupus erythematosus (SLE) is associated with high rates of cardiovascular disease. However, research has shown that aggressive risk assessment with lipid screenings and treatment with statins may be suboptimal for these patients. A new study compared the rates of screening and treatment between SLE patients, diabetes mellitus patients and the general Medicaid population. The results: Despite having an elevated risk of CVD, SLE patients received less lipid testing and fewer statin prescriptions than other patients…

Moderate Liver Enzyme Elevation Found in Patients With & Without Hepatic Steatosis

Carina Stanton | January 2, 2019

Limited data are available on liver enzyme elevation in patients with RA, PsA and psoriasis being treated with tofacitinib and methotrexate. But early study findings are shedding light on the nature and risks of liver enzyme levels in these patients…

Patients with Prediabetes May Be Predisposed to Arthritis

Lara C. Pullen, PhD | January 2, 2019

New research from the CDC shows that approximately one-third of U.S. adults with prediabetes also have arthritis, which can prevent physical activity in these patients, thereby, making it more likely they will develop type 2 diabetes…

Ultrasound as RA Treat-to-Target Strategy Doesn’t Improve Long-Term Outcomes

Larry Beresford | December 18, 2018

An analysis of treat-to-target therapy assessing two ultrasound definitions of remission for patients with early rheumatoid arthritis (RA) has concluded that using ultrasound remission as a target was not associated with better long-term outcomes for RA patients.1 Compared with MRI, ultrasound costs less, is more accessible and offers the ability to scan more joints in…

AFLAR Experts Discuss Highlights, Hurdles in Rheumatology in Africa

Thomas R. Collins | December 18, 2018

CHICAGO—Rheumatology physicians and researchers from Africa said the field’s resources and medical literature on the continent are slowly expanding, but they repeatedly lamented that the millions who suffer from rheumatic diseases there have major obstacles to overcome to access care. Their reviews and assessments—sometimes grim and sometimes hopeful—came in a session that was a joint…

Bimekizumab Promising for PsA

Michele B. Kaufman, PharmD, BCGP | December 18, 2018

CHICAGO—Bimekizumab is an investigational interleukin (IL) 17A and IL-17 neutralizing agent being studied to modulate inflammation in psoriasis, psoriatic arthritis and ankylosing spondylitis. During the late-breaking abstract session at the 2018 ACR/ARHP Annual Meeting, researchers reported on the results of a 48-week, Phase 2b, randomized, double-blind, placebo-controlled study of bimekizumab in patients with active psoriatic…

Study Assesses the Role of Genetics & the Gut in Reactive Arthritis

Mary Beth Nierengarten | December 18, 2018

Genes may predispose people to have certain microbial signatures in their gut that, in turn, make them susceptible to developing reactive arthritis. This is the main finding of a recent study in which researchers investigated whether perturbations in the intestinal microbiome play a role in susceptibility to reactive arthritis in the face of triggers, such…